F90.0
Conditions
Interventions
Group 1: Retrospective routine-care cohort of adult patients with a documented ADHD diagnosis and ADHD pharmacotherapy in the psychiatric outpatient clinics of LVR-Klinik Bonn between 1 January 2015 a
Sponsors
LVR-Klinik Bonn
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Adult patients aged 18 years or older with a documented ADHD diagnosis according to ICD-10 F90.0 who were treated in the psychiatric outpatient clinics of LVR-Klinik Bonn between 1 January 2015 and 31 December 2025, who initiated ADHD pharmacotherapy during this period, and whose medication course is sufficiently traceable in the outpatient clinical documentation are included.
Exclusion criteria
Exclusion criteria: Patients younger than 18 years, patients without a documented ADHD diagnosis according to ICD-10 F90.0, patients without documented ADHD pharmacotherapy during the observation period, and cases in which the medication course is not sufficiently traceable in the outpatient clinical documentation are excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome is the time from initiation of ADHD pharmacotherapy to the first documented treatment change. A treatment change is defined as either a documented switch to another ADHD medication or documented discontinuation of ADHD pharmacotherapy. The outcome is assessed retrospectively over each patient’s individual observation period, starting with the date of the first documented ADHD medication and ending with the date of the first documented treatment change or, if no treatment change was documented, with the last documented outpatient contact. Data are collected exclusively from existing routine clinical documentation, particularly from medical records and the clinical information system of LVR-Klinik Bonn. No additional examinations, surveys or patient contacts are performed. | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of documented medication changes per patient during follow-up; documented reasons for treatment changes, including adverse effects, insufficient efficacy, patient preference and adherence/compliance problems; differences in treatment persistence and switching rates between medication classes and specific substances; associations of age at treatment initiation and sex with the risk of treatment change. | — |
Countries
Germany
Contacts
Public ContactDaniel Huys
LVR-Klinik Bonn
Outcome results
None listed